PLoS By Category | Recent PLoS Articles

Biochemistry - Critical Care and Emergency Medicine - Pathology - Physiology

Antibody Phage Display Assisted Identification of Junction Plakoglobin as a Potential Biomarker for Atherosclerosis
Published: Wednesday, October 24, 2012
Author: Seraina Cooksley-Decasper et al.

by Seraina Cooksley-Decasper, Hans Reiser, Daniela S. Thommen, Barbara Biedermann, Michel Neidhart, Joanna Gawinecka, Gieri Cathomas, Fabian C. Franzeck, Christophe Wyss, Roland Klingenberg, Paolo Nanni, Bernd Roschitzki, Christian Matter, Petra Wolint, Maximilian Y. Emmert, Marc Husmann, Beatrice Amann-Vesti, Wilibald Maier, Steffen Gay, Thomas F. L├╝scher, Arnold von Eckardstein, Danielle Hof

To date, no plaque-derived blood biomarker is available to allow diagnosis, prognosis or monitoring of atherosclerotic vascular diseases. In this study, specimens of thrombendarterectomy material from carotid and iliac arteries were incubated in protein-free medium to obtain plaque and control secretomes for subsequent subtractive phage display. The selection of nine plaque secretome-specific antibodies and the analysis of their immunopurified antigens by mass spectrometry led to the identification of 22 proteins. One of them, junction plakoglobin (JUP-81) and its smaller isoforms (referred to as JUP-63, JUP-55 and JUP-30 by molecular weight) were confirmed by immunohistochemistry and immunoblotting with independent antibodies to be present in atherosclerotic plaques and their secretomes, coronary thrombi of patients with acute coronary syndrome (ACS) and macrophages differentiated from peripheral blood monocytes as well as macrophage-like cells differentiated from THP1 cells. Plasma of patients with stable coronary artery disease (CAD) (n?=?15) and ACS (n?=?11) contained JUP-81 at more than 2- and 14-fold higher median concentrations, respectively, than plasma of CAD-free individuals (n?=?13). In conclusion, this proof of principle study identified and verified JUP isoforms as potential plasma biomarkers for atherosclerosis. Clinical validation studies are needed to determine its diagnostic efficacy and clinical utility as a biomarker for diagnosis, prognosis or monitoring of atherosclerotic vascular diseases.